AIM
STOK icon

Anchor Investment Management’s Stoke Therapeutics STOK Stock Holding History

Anchor Investment Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-66
Closed -$2.56K – 986
2021
Q1 		$2.56K Hold
66
– – ﹤0.01% 849
2020
Q4 		$4.09K Hold
66
– – ﹤0.01% 776
2020
Q3 		$2.21K Hold
66
– – ﹤0.01% 810
2020
Q2 		$1.57K Sell
66
-106
-62% -$2.52K ﹤0.01% 808
2020
Q1 		$3.94K Hold
172
– – ﹤0.01% 711
2019
Q4 		$4.87K Buy
+172
New +$4.33K ﹤0.01% 708

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Anchor Investment Management's STOK Position: Q2 2021 in Review

Anchor Investment Management sold out of Stoke Therapeutics (STOK) in Q2 2021, closing a stake of 66 shares — an estimated $2.56K sold.

Anchor Investment Management first reported a position in STOK in Q4 2019 and held it in 6 quarters. The position peaked at $4.87K in Q4 2019. 97 funds tracked by Wall St. Rank hold STOK as of Q2 2021.

  • Anchor Investment Management reported no remaining Stoke Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Anchor Investment Management sold 66 Stoke Therapeutics shares in Q2 2021, an estimated $2.56K.
  • Anchor Investment Management first reported a position in Stoke Therapeutics in Q4 2019 and held it in 6 quarters.
  • Anchor Investment Management's Stoke Therapeutics position peaked at $4.87K in Q4 2019.
  • 97 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2021.

Based on Anchor Investment Management's 13F filing for Q2 2021, filed 2 Jan 2024.